Medtronic Pacemaker Recall Issued for Consulta and Syncra Implants

Medtronic has sent a letter to hospitals and health care providers about potential manufacturing problems with Consulta and Syncra implantable pacemakers.

The Medtronic Consulta and Syncra pacemaker recall was announced by the FDA on July 16, after an urgent field safety notice (PDF) was sent out by Medtronic last month.

The devices, known as cardiac resynchronization therapy pacemakers (CRT-Ps) may have certain manufacturing defects, which could pose a potential risk for patients. However, there have been no injuries or adverse events reported in connection to the problem, according to the FDA.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

“This issue was identified as a result of an internal investigation that indicated a recent trend of increasing manufacturing rejects related to the weld of the connector bracket,” Medtronic wrote to its customers. “An out-of-specification weld could result in a loss of device hermeticity and compromise device functionality.”

The recall only affects non-implanted Consulta CRT-P Model C4TR01 and C3TR01 (not approved for use in the U.S.) and Syncra CRT-P Model C2TR01 devices manufactured between April 1 and May 13, 2013. The company made no recommendations regarding devices that have already been implanted in patients. The FDA announcement includes a full list of serial numbers of affected devices.

Medtronic is calling for the non-implanted devices affected by the recall to be returned for inspection. The company also wants implanted devices affected by the recall registered by calling the Medtronic Patient Registration Department at (800) 848-9300. Customers with questions can also call (763) 526-6000.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S.
Depo-Provera Brain Tumor Warnings Added to Drug Label in Europe, But Not In U.S. (Posted yesterday)

A recently filed Depo-Provera lawsuit questions why Pfizer updated the drug label in Europe, to warn about the risk of meningioma brain tumors, but failed to provide the same Depo-Provera warnings to U.S. consumers and doctors.

Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week
Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week (Posted 3 days ago)

U.S. District Judge presiding over all federal hair relaxer lawsuits will meet with lawyers involved in the litigation on Thursday, to discuss the status of the claims and when to move forward with bellwether cases.